New York State Common Retirement Fund Sells 5,406 Shares of IQVIA Holdings Inc. (NYSE:IQV)

New York State Common Retirement Fund trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,522 shares of the medical research company’s stock after selling 5,406 shares during the quarter. New York State Common Retirement Fund owned approximately 0.06% of IQVIA worth $20,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. grew its position in shares of IQVIA by 266.5% during the 3rd quarter. Blue Trust Inc. now owns 1,030 shares of the medical research company’s stock worth $244,000 after buying an additional 749 shares during the period. Private Advisor Group LLC raised its position in IQVIA by 13.2% in the 3rd quarter. Private Advisor Group LLC now owns 5,746 shares of the medical research company’s stock valued at $1,362,000 after buying an additional 668 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of IQVIA by 26,871.1% during the 3rd quarter. International Assets Investment Management LLC now owns 40,996 shares of the medical research company’s stock worth $9,715,000 after buying an additional 40,844 shares in the last quarter. Brighton Jones LLC grew its stake in IQVIA by 9.4% in the 3rd quarter. Brighton Jones LLC now owns 1,038 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 89 shares during the period. Finally, CENTRAL TRUST Co increased its holdings in IQVIA by 35.0% during the third quarter. CENTRAL TRUST Co now owns 690 shares of the medical research company’s stock worth $163,000 after buying an additional 179 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Trading Down 1.6 %

IQVIA stock opened at $190.94 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The stock has a market cap of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. The firm’s fifty day moving average price is $199.57 and its 200-day moving average price is $216.49.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.